The Finnish Diabetes Risk Score (FINDRISC) as a screening tool for hepatic steatosis

References

• Preiss D, Sattar N. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin Sci (Lond). 2008;115:141–50.
   PubMed Web of Science ®Google Scholar
• Cortez-Pinto H, Camilo ME. Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): diagnosis and clinical course. Best Pract Res Clin Gastroenterol. 2004;18:1089–104.
   PubMedGoogle Scholar
• Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, . M. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia. 2005;48:634–42.
   PubMed Web of Science ®Google Scholar
• Gastaldelli A, Kozakova M, Hojlund K, Flyvbjerg A, Favuzzi A, Mitrakou A, . Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology. 2009;49:1537–44.
   PubMed Web of Science ®Google Scholar
• Joseph AEA, Saverymuttu SH, Al-Sam S, Cook MG, Maxwell JD. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin Radiol. 1991;43:26–31.
   PubMed Web of Science ®Google Scholar
• Ahmeda MH, Abua EO, Byrne CD. Non-alcoholic fatty liver disease (NAFLD): New challenge for general practitioners and important burden for health authorities? Prim Care Diabetes. 2010;4:129–37.
   PubMedGoogle Scholar
• Lindström J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care. 2003;26:725–31.
   PubMed Web of Science ®Google Scholar
• Saaristo T, Peltonen M, Lindström J, Saarikoski L, Sundvall J, Eriksson JG, . Cross-sectional evaluation of the Finnish Diabetes Risk Score: a tool to identify undetected type 2 diabetes, abnormal glucose tolerance and metabolic syndrome. Diab Vasc Dis Res. 2005;2:67–72.
   PubMedGoogle Scholar
• Franciosi M, De Berardis G, Rossi MC, Sacco M, Belfiglio M, Pellegrini F, . Use of the diabetes risk score for opportunistic screening of undiagnosed diabetes and impaired glucose tolerance: the IGLOO (Impaired Glucose Tolerance and Long-Term Outcomes Observational) study. Diabetes Care. 2005;28:1187–94.
   PubMed Web of Science ®Google Scholar
• Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, . Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007;28:88–136.
   PubMed Web of Science ®Google Scholar
• Silventoinen K, Pankow J, Lindström J, Jousilahti P, Hu G, Tuomilehto J. The validity of the Finnish Diabetes Risk Score for the prediction of the incidence of coronary heart disease and stroke, and total mortality. Eur J Cardiovasc Prev Rehabil. 2005;12:451–8.
   PubMedGoogle Scholar
• Schwarz PE, Li J, Reimann M, Schutte AE, Bergmann A, Hanefeld M, . The Finnish Diabetes Risk Score is associated with insulin resistance and progression towards type 2 diabetes. J Clin Endocrinol Metab. 2009;94:920–6.
   PubMed Web of Science ®Google Scholar
• Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med. 1998;158:1789–95.
   PubMed Web of Science ®Google Scholar
• Perloff D, Grim C, Flack J, Frohlich ED, Hill M, McDonald M, . Human blood pressure determination by sphygmomanometry. Circulation. 1993;88 (5 Pt 1):2460–70.
   PubMedGoogle Scholar
• Fletcher GF, Balady GJ, Amsterdam EA, Chaitman B, Eckel R, Fleg J, . Exercise standards for testing and training: a statement for healthcare professionals from the American Heart Association. Circulation. 2001;104;1694–740.
   PubMed Web of Science ®Google Scholar
• Bellentani S, Saccoccio G, Masutti F, Crocè LS, Brandi G, Sasso F, . Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 2000;132:112–7.
   PubMed Web of Science ®Google Scholar
• Kahn SH. The ‘lipid accumulation product’ performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovasc Disord. 2005;5:26.
   PubMedGoogle Scholar
• Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, . The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33.
   PubMed Web of Science ®Google Scholar
• Bailey SM, Mantena SK, Millender-Swain T, Cakir Y, Jhala NC, Chieng D, . Ethanol and tobacco smoke increase hepatic steatosis and hypoxia in the hypercholesterolemic apoE(−/−) mouse: implications for a ‘multihit’ hypothesis of fatty liver disease. Free Radic Biol Med. 2009;46:928–38.
   PubMed Web of Science ®Google Scholar
• Bradley KA, Boyd-Wickizer J, Powell SH, Burman ML. Alcohol screening questionnaires in women: a critical review. JAMA. 1998;280:166–71.
   PubMed Web of Science ®Google Scholar
• Sargin M, Uygur-Bayramicli O, Sargin H, Orbay E, Yayla A. Association of nonalcoholic fatty liver disease with insulin resistance: is OGTT indicated in nonalcoholic fatty liver disease? J Clin Gastroenterol. 2003;37:399–402.
   PubMedGoogle Scholar
• Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221–31.
   PubMed Web of Science ®Google Scholar
• Clark JM, Diehl AM. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JAMA. 2003;289:3000–4.
   PubMed Web of Science ®Google Scholar
• Marques MD, Santos RD, Parga JR, Rocha-Filho JA, Quaglia LA, Miname MH, . Relation between visceral fat and coronary artery disease evaluated by multidetector computed tomography. Atherosclerosis. 2010;209:481–6.
   PubMedGoogle Scholar
• Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ; Nash Clinical Research Network. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7: 1104–12.
   PubMed Web of Science ®Google Scholar
• Lindström J, Peltonen M, Eriksson JG, Aunola S, Hämäläinen H, Ilanne-Parikka P, . Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care. 2008;31:857–62.
   PubMed Web of Science ®Google Scholar